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Protein kinase B/Akt has been described as a central mediator of antiapoptotic signals in cancer cells. Furthermore, Akt has been
shown to affect cell cycle progression and proliferative pathways and to possess a potential function in tumorigenesis and
chemoresistance. In this study, we show that the ectopic expression of a constitutively active form of Akt1 (CA-Akt1) results in
enhanced chemoresistance of NCI H460 human NSCLC cells towards a panel of chemotherapeutic agents. To understand the
molecular alterations leading to impaired chemosensitivity mediated by activated Akt, we analysed various apoptotic pathways,
including the activation of p53, caspases 3, 7, 8, and 9, release of cytochrome c from mitochondria, and the expression levels of pro-
and antiapoptotic proteins such as Bcl-2, Bcl-xL, Bcl-xs, Bax, or Bfl-1. We observed that expression of CA-Akt did not interfere with
single defined apoptotic switches, but modulated the apoptotic threshold of several apoptotic pathways towards increasing the
threshold of onset. In particular, we found that CA-Akt-expressing cells displayed increased expression of the antiapoptotic Bcl-2
family member protein Bcl-xl, and a delayed onset of the p53 pathway after treatment with cisplatin or Mitoxantrone. Thus, our data
suggest that Akt mediates chemoresistance in NHI H460 cells by interfering with and delaying the onset of various apoptotic
pathways. A complete inactivation of apoptotic pathways was observed in none of the molecular alterations investigated. Our data
strengthen the role of Akt as a central mediator of cell survival signals and/or chemoresistance and as an attractive target for cancer
cell chemosensitisation.
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The process of malignant transformation requires cells to undergo
a variety of molecular alterations to acquire growth properties that
allow them to divide indefinitely and in an uncontrolled fashion
under conditions of low oxygen and poor nutrient supply. Such
conditions would normally induce programmed cell death, and
malignant cells additionally have to acquire molecular mechanisms
to evade apoptotic stimuli in order to survive and to form solid
tumours. It is conceivable that antiapoptotic signalling cascades
play an equally important role in the development of the
pathological cancer phenotype as the dysregulation of proliferative
signalling cascades.
Phosphatidyl-inositol 3-kinase (PI3K), which relays various
signalling pathways via the production of phosphatidyl-inositide
lipids, has been identified as a central mediator of cell growth,
metabolism, migration, and survival (reviewed in Wymann et al,
2003). PI3K regulates cellular functions by recruiting PI(3, 4, 5)P3
binding proteins to the plasma membrane preferentially via pH
domains. The prototype of these molecules is protein kinase B/Akt.
Binding to PI(3, 4, 5)P3 results in a conformational change which
makes Akt susceptible to phosphorylation at threonine 308 and
serine 473 (Alessi and Cohen, 1998). Phosphorylation of Akt
results in its activation and dissociation from the membrane. The
resolution of the crystal structures of activated Akt and inactive
Akt2 has provided further clues about their regulation and
activation (Yang et al, 2002; Huang et al, 2003). Substrates of
Akt are phosphorylated within the consensus sequence RXRXXS/T
(Obata et al, 2000). Several target proteins of Akt involved in
antiapoptotic signalling, the regulation of the cell cycle, and insulin
homeostasis have been described.
GSK3 was the first protein known to be inactivated by Akt via
phosphorylation at serine 9 (Cross et al, 1995). Besides the
regulation of glycogen synthesis, GSK3 regulates several intracel-
lular signalling pathways including AP1 (Scalia et al, 2001), CREB
(Cross et al, 1995), and the tumour-suppressor gene product APC
(Zumbrunn et al, 2001). Akt can promote cellular survival by
inhibiting proteins involved in the regulation of apoptosis. One
such mechanism is the phosphorylation of the proapoptotic
protein Bad at serine 136 by Akt, which creates a binding site
for 14-3-3 proteins and thereby prevents Bad from binding
and inhibiting the antiapoptotic protein Bcl-xL (Datta et al,
1997). Another direct mechanism is the Akt-mediated phosphor-
ylation of caspase 9 at serine 196 inhibiting its protease- and
apoptosis-initiating activity (Cardone et al, 1998). c-FLIP, a
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tumour cell lines on a transcriptional level by the Akt pathway
through a yet unknown mechanism (Panka et al, 2001). The
apoptosis signal-regulating kinase 1 (Ask1) is phosphorylated by
Akt at serine 83, leading to its inhibition and a reduced activation
of JNK, which under certain circumstances can promote apoptosis
(Kim et al, 2001). The forkhead transcription factor FKHRL1 is
phosphorylated by Akt at threonine 32 and serine 253, resulting in
its retention in the cytoplasm by 14-3-3 proteins. Thus, FKHRL1-
mediated transcription of proapoptotic proteins such as the Fas
ligand is reduced and cell survival is promoted (Brunet et al, 1999).
Other substrates of Akt include phosphofructokinase 2 (Deprez
et al, 1997), Ik-B kinase from the NF-kB pathway (Ozes et al,
1999), and endothelial NO synthase (Dimmeler et al, 1999).
Akt can influence proliferative and cell cycle regulatory path-
ways and thereby indirectly modulate tumour chemosensitivity by
the regulation of Cyclin D stability (Muise-Helmericks et al, 1998)
and inhibition of p27
Kip1 protein levels (Collado et al, 2000).
Furthermore, Akt has been shown to directly phosphorylate the
cyclin-dependent kinase inhibitors p21
WAF1 at threonine 145 and
serine 146 (Zhou et al, 2001) and p27
Kip1 at threonine 157 (Liang
et al, 2002), leading to their cytosolic retention and neutralisation
of their growth-inhibitory effect. In addition, cytoplasmic p21
WAF1
binds to ASK1-inhibiting apoptosis (Asada et al, 1999). The p53
pathway is influenced by Akt through phosphorylation of the p53-
regulating protein MDM2 at residues serine 166 and 186 (Mayo
and Donner, 2001). Akt-mediated phosphorylation of MDM2
results in the translocation of MDM2 from the cytoplasm into the
nucleus, leading to reduced cellular p53 protein levels and
decreased p53 transcriptional activity.
Since PKB/Akt is involved in such a multitude of apoptosis
regulatory pathways, it is not surprising that Akt is overexpressed
in a variety of human tumour cell lines and cancers (Bellacosa et al,
1995; Ringel et al, 2001; Roy et al, 2002) and a mediator of
oestrogen resistance in breast cancer cells (Campbell et al, 2001).
Akt activity in cancers can either be deregulated by constitutive
activation or by mutation of PTEN/MMAC1, a phosphatase that
directly counteracts Akt through the dephosphorylation of PI-3-,
4-, and 5-P3 (Stambolic et al, 1998). Besides being overexpressed or
constitutively activated in certain types of cancer, Akt has been
implicated in modulating sensitivity of cancer cells towards
standard chemotherapy (Hayakawa et al, 2000; Page et al, 2000;
Schmidt et al, 2002; Knuefermann et al, 2003).
Although many apoptotic pathways modulated by Akt have been
described, relatively little is known about the actual molecular
mechanisms by which Akt suppresses apoptosis after chemothera-
peutic treatment of cancer cells. To establish a cellular system that
allows in-depth analysis of these pathways, we transfected NCI
H460 human NSCLC cells with an expression vector encoding a
constitutive form of Akt1 (Schmidt et al, 2002). Here we describe
the effects of CA-Akt1 on the modulation of chemosensitivity
towards several chemotherapeutic regimen in stable cell clones of
NCI H460 NSCLC cells. Furthermore, we describe molecular
alterations in various apoptotic pathways that may account for the
desensitising effects observed in CA-Akt1-expressing NCI H460
cells.
MATERIALS AND METHODS
Materials
Anti-Akt, anti-phospho-Akt, anti-GSK, anti-PARP, and anti-
caspase antibodies were obtained from Cell Signalling Technology,
Inc. (Beverly, MA, USA); anti-Bcl2, anti-Bcl-xs/l, anti-A1/Bfl-1,
anti-Bax, and anti-p53 antibodies were purchased from Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA, USA); anti-MDM2 antibody
was obtained from Oncogene Research Products (Boston, MA,
USA); M2 anti-FLAG antibody, b-actin antibody, and all other
reagents were purchased from Sigma Chemical (St Louis, MO,
USA) unless otherwise specified.
Cells and cell culture
NCI H460 human lung cancer cells were obtained from ATCC and
maintained in RPMI 1640 medium supplemented with 10% FBS,
2m ML -glutamin, 100uml
 1 penicillin G, and 100mgml
 1 strepto-
mycin.
Establishment of farnesylated Akt1 expression clones in
NCI H460 cells
NCI H460 cells were transfected with pcDNA3.1. Hygro vector
containing farnesylated Akt1 devoid of the PH domain described
earlier (Schmidt et al, 2002). Transfection was performed with the
Fugene-6 transfection kit (Roche Diagnostics, Indianapolis, IN,
USA) according to the manufacturer’s recommendations. Stable
NCI H460 clones were selected in medium containing 50mgml
 1
Hygromycin B (Roche Diagnostics, Indianapolis, IN, USA). Stable
clones were analysed for expression of ectopic FLAG-tagged Akt1
devoid of its PH domain and containing the farnesylation sequence
by immunoblotting with the M2 antibody specific for the FLAG
tag. Clones that were both, resistant towards the respective
antibiotic and positive on protein level, were selected for further
studies. Clones expressing farnesylated Akt1 were named NCI
H460-Akt1. Experiments were conducted with at least two different
clones.
Cytotoxicity assay
Cells were seeded in 100ml medium supplemented with 0.5% FCS
into 96-well culture plates. After 24h incubation, cells were treated
with various doses of chemotherapeutic drugs as indicated in 50ml
volume. At 72h after addition of the compounds, cell viability was
assayed by adding 75ml of 1mgml
 1 sodium 30-[1-(phenyl amino
carbonyl-3,4-tetrazolium]-bis (4-methoxy-6-nitro-) benzene sul-
phonic acid (XTT) in RPMI containing 7.66mgml
 1 N-methyl
dibenzopyrazin methyl sulphate (PMS). After incubating the cells
for 3h at 371Ci naC O 2 incubator, cell viability was determined by
measuring the optical absorbance at a wavelength of 490nm and
normalization with the corresponding control cells. Each concen-
tration was assayed in quadruplicates and the assay for each
cytostatic was independently repeated at least three times.
Immunoblot analysis
Cells were lysed in a buffer containing 50mM Tris, pH 7.4, 150mM
NaCl, 1% NP-40, 50mM NaF, 1mM Na3VO4, and 1mM phenyl-
methylsulphonyl fluoride. Lysates were cleared by centrifugation
and supernatants were collected. Equal amounts of lysate protein
were used for Western blot analysis with antibodies as indicated.
Specific signals were visualised by use of the ECL chemolumines-
cence detection kit (Amersham, Braunschweig, Germany).
Determination of Akt1 phosphorylation
Cells were seeded onto six-well plates in medium containing 0.5%
serum. After starvation overnight, cells were stimulated for 15min
with medium containing 10% serum or medium additionally
supplemented with a cocktail containing each 10ngml
 1 of EGF,
PDGF, and IGF-1. Cell lysates were then analysed in immunoblot
assays with antibodies specific for phospho-Akt (Thr 308) or
phospho-Akt (Ser 473). Signals were visualised by use of the ECL
chemoluminescence detection kit (Amersham, Braunschweig,
Germany).
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The Akt kinase assay was performed using the Akt Kinase Assay
Kit from Cell Signalling Technology, Inc. with GSK-3 fusion
protein as substrate. Cells were seeded out in 10cm dishes and
switched to medium containing 0.5% serum after attachment.
After starvation overnight, cells were either kept unstimulated or
were stimulated for 20min with medium containing 10% FCS
supplemented with a cocktail containing each 10ngml
 1 of EGF,
PDGF, and IGF-1. Cells were lysed and lysates clarified by
centrifugation. Supernatants were swirled for 3h at 41C with an
anti-Akt-agarose conjugate. After three times washing with lysis
buffer and with kinase buffer, the immunoprecipitates were
subjected to an in vitro kinase reaction with 40ml of reaction
mixture containing kinase reaction buffer supplemented with
200mM ATP and 1mg GSK-3-fusion protein. The reaction was
allowed to process at 301C for 30min and stopped by boiling the
samples in SDS sample buffer for 5min. Immunoprecipitates were
separated by 12.5% SDS–PAGE and then analysed in immunoblot
assays with antibodies specific for phospho-GSK (Ser 21/9) and
Akt. Signals were visualised with the ECL chemoluminescence
detection kit (Amersham, Braunschweig, Germany).
Colorimetric detection of caspase activation
The activation of the initiator caspases 8 and 9, as well as the
effector caspase 3, was determined by in vitro assays with cell
lysates using the caspase 3 cellular activity assay kit, the caspase 8
assay kit (both Calbiochem-Novabiochem, San Diego, CA, USA),
and the caspase 9 colorimetric assay kit (R&D Systems,
Minneapolis, MN, USA). Cells were seeded out in 10-cm dishes
and switched to medium containing 0.5% serum after attachment.
After starvation overnight, cells were treated with 400nM
Mitoxantrone or 20mM cisplatin for 24 and 36h, respectively.
Cells were lysed and lysates were clarified by centrifugation.
Supernatants were subjected to caspase activity assays according to
the manufacturer’s recommendations with specific peptide sub-
strates (DEVD-pNA for caspase 3, Ac-IETD-pNA for caspase 8,
and LEHD-pNA for caspase 9). Active caspases lead to the
proteolytic cleavage of the peptide substrates and thereby the
release of p-nitroanilin, which was quantified with the Victor
Multilabel Counter at a wave length of 405nm.
Fractional centrifugation and cytochrome c ELISA
For analysing the distribution of cytochrome c between mitochon-
dria and cytosol cells were fractionally centrifuged and a
cytochrome c ELISA (EMD Biosciences, Inc., San Diego, CA,
USA) was performed. Cells were seeded out in 10-cm dishes and
switched to medium containing 0.5% serum after attachment.
After starvation overnight, cells were treated with 400nM
Mitoxantrone or 20mM cisplatin for 8h. After treatment, cells
were removed from the dish, resuspended in buffer A (20mM
Hepes-KOH, pH 7.5, 10mM KCl, 1.5mM MgCl2,1m M EDTA, 1mM
EGTA, 1mM DTT, 250mM sucrose, and protease inhibitors), and
homogenised using a teflon homogeniser. The homogenate was
centrifugated to remove cellular debris (2000g/10min). The
supernatant was again centrifugated (12500g/30min) and 500ml
solubilisation buffer (from caspase 9 colorimetric assay kit) was
added to the supernatant representing the cytosolic fraction. The
pellet was resuspended in 500ml buffer B (250ml buffer A plus
250ml solubilisation buffer) representing the mitochondrial frac-
tion. Both fractions were subjected to cytochrome c ELISA assays
according to the manufacturer’s specifications. For each sample,
the relative distribution of cytochrome c between cytosolic and
mitochondrial fraction was calculated.
RESULTS
Ectopic expression of farnesylated Akt1 mediates
chemoresistance in NCI H460 human lung cancer cells
To establish a cellular system that allows to analyse mechanisms of
chemoresistance directly related to Akt, we stably transfected NCI
H460 human NSCLC cells with an expression vector for
constitutively active Akt. This plasmid encoded for Akt1 devoid
of its N-terminal PH domain (replaced by a FLAG tag for antibody
detection). To target Akt1 to the membrane for constitutive
activation, we inserted a C-terminal sequence tag encoding a
farnesylation motif and a stretch of basic amino acids (Schmidt
et al, 2002).
Single-cell clones were analysed for ectopic expression of Akt1
by immunoblot analysis of cell lysates with an M2 anti-FLAG
antibody, and positive clones (NCI H460-Akt1) were used in this
study. To assess whether ectopically expressed farnesylated Akt1
was phosphorylated at threonine 308 and serine 473, selected
clones were analysed in immunoblots for their phosphorylation
status at these residues (Figure 1). NCI H460-Akt1 cells were
starved for 16h and then stimulated with medium containing 10%
serum or 10% serum plus growth factors (EGF, PDGF, and IGF-1).
Cells were transfected with the empty vector were used as controls.
The results are shown in Figure 1A: endogenous Akt1 was detected
as a protein migrating at an Mr around 66kDa, whereas ectopically
expressed CA-Akt1 was detected with both, anti-Akt1 and anti-
FLAG antibodies as a protein with an Mr of about 50kDa (due to
the lack of the PH domain). Phosphorylation of endogenous Akt1
at Ser473 was induced by stimulation of cells with a growth factor
cocktail, and, to a lesser extent, by stimulation with serum alone,
while phosphorylation at Thr308 was hardly detectable. In
contrast, farnesylated Akt1 was phosphorylated at both residues
irrespective of serum conditions or growth factor stimulation.
To determine the kinase activity of endogenous and ectopically
expressed farnesylated Akt1, an in vitro kinase assay with
immunoprecipitated Akt from cell lysates and GSK-3-fusion
protein as substrate was performed under conditions as described
for Figure 1A (for details, see Materials and methods). As shown in
Figure 1B, endogenous Akt1 in control cells exhibited no
detectable kinase activity after serum deprivation, but stimulation
with serum and growth factors strongly induced kinase activity. In
immunoprecipitates from NCI H460-Akt1 cells, kinase activity
from ectopically expressed Akt1 could already be detected under
serum-free conditions. Upon serum and growth factor stimulation,
Akt kinase activity was induced to a much greater extent as in
control cells. The results from the in vitro kinase assay and from
the immunoblot analysis of Akt1 phosphorylation status show that
ectopically expressed farnesylated Akt1 is constitutively activated
in human NCI H460-Akt1 cells and that these cells display a higher
Akt kinase activity than control cells irrespective of medium
conditions. Surprisingly, we observed that CA-Akt1 transfected
clones displayed a slight growth retardation compared to control
transfected cells (Figure 1C). Analysis of the expression levels for
the cell cycle inhibitors p21
Waf1 and p27
Kip1, respectively, revealed
no changes in protein abundance. However, we observed a reduced
electrophoretic mobility of p21
Waf1 in NCI H460-Akt1 cells, which
might be indicative of increased p21
Waf1 phosphorylation
(Figure 1D).
To assess whether the ectopic expression of CA-Akt1 modulates
the cellular response to treatment with chemotherapeutic regimen,
we compared the sensitivity of control transfected human NCI
H460 cells with the sensitivity of NCI H460-Akt1 cells towards a
panel of chemotherapeutics, namely cisplatin, Mitoxantrone, 5-
fluoruracil, doxorubicin, and paclitaxel. The viability of the cells
after incubation with the substances for 72h was determined with
a standard XTT assay as described in Materials and methods. The
most striking differences were observed with the DNA alkylating
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doxorubicin: NCI H460-Akt1 cells displayed a 20-fold increased
resistance towards the DNA alkylating agent Mitoxantrone as
compared to control cells (IC50 0.1 vs 0.005mM, respectively). An
approximately 10-fold decreased sensitivity was observed upon
treatment with the DNA alkylating agent cisplatin, whereas a 14-
fold decrease in chemosensitivity was measured with the
anthracycline doxorubicin (Figure 2). Only small changes in
chemosensitivity have been observed after incubation with the M-
Phase specific tubulin inhibitor paclitaxel or the antimetabolite 5-
fluorouracil (2.5- and 3-fold decrease, respectively) which primar-
ily acts in the S-phase of the cell cycle. The IC50 values towards the
various chemotherapeutics are summarised in Table 1. Impor-
tantly, the differential chemoresistance was only detected when
cells were grown in low serum. If cells were cultured under normal
medium conditions, the activation of endogenous Akt through
serum components probably suffices to activate Akt-dependent
antiapoptotic pathways. These data suggest that the expression of
activated Akt1 in human NCI H460 NSCLC cells can desensitise
this cell line especially towards DNA reactive chemotherapeutics,
but – at least in our system – does hardly alter the sensitivity
towards cell cycle specific agents such as paclitaxel.
Modulation of apoptotic pathways by CA-Akt1 after
chemotherapeutic treatment of NCI H460 lung cancer cells
Most of the chemotherapeutics kill tumour cells via the induction
of apoptosis (Kaufmann and Earnshaw, 2000). To understand the
molecular alterations that lead to decreased chemosensitivity of
NCI H460-Akt1, we examined several apoptotic pathways and
executors and focused our analyses on cisplatin- and Mitoxan-
trone-induced cell death, which were found to be most strongly
influenced by CA-Akt1.
A very sensitive cell death ELISA detecting histone-associated
DNA fragments was initially employed to determine the time
Figure 1 (A) Expression and activation of ectopically expressed
farnesylated Akt1 in NCI H460 cells. Control transfected NCI H460 cells
or cells expressing farnesylated Akt1 were serum starved overnight (-) and
then stimulated for 15min with medium containing 10% FCS (S) or 10%
FCS plus a cocktail of 10ngml
 1 each EGF, IGF-1, and PDGF (GF). Cell
lysates were analysed by immunoblotting with antibodies specific for Akt1,
FLAG-epitope, phospho-Akt (Thr 308) or phospho-Akt (Ser 473) as
indicated. The ectopically expressed farnesylated Akt1 devoid of the PH
domain migrates at an MW of approximately 50kDa. (B) Akt kinase
activity in NCI H460-Akt1 cells and in control cells. Cells were serum
starved for 16h and then stimulated as described above. Endogenous Akt1
from control transfected cells and endogenous Akt1 plus farnesylated Akt1
from NCI H460-Akt1 cells were immunoprecipitated with an Akt1 specific
antibody. Immunoprecipitates were used in kinase assay reactions with
GSK-3-fusion protein as substrate. Immunoblots of the reactions were
assayed with antibodies specific for phospho-GSK (Ser 21/9) (lower panel)
and Akt1 (upper panel). (C) Proliferation rates of NCI H460 control
transfectants and NCI H460-Akt1 cells. 3 10
4 cells (as indicated) per well
were seeded into six wells into a medium containing 0.5% FCS. At the
indicated time points, the cells were harvested by trypsinisation and cell
numbers were determined using a Coulter counter. Each sample was
determined in triplicates. Two independent NCI H460-Akt1 cell clones
were analysed. (D) Expression analysis of p21
Waf1 and p27
Kip1 in NCI
H460-Akt1 cells vs control cells. Cell lysates were analysed by
immunoblotting with antibodies specific for p21
Waf1, p27
Kip1, and b-actin
as a loading control.
(M)
(
%
)
(
%
)
(M) (M) C
Figure 2 Decreased chemosensitivity of NCI H460-Akt1 cells towards
doxorubicin, cisplatin, and Mitoxantrone. Control transfected NCI H460
cells (filled squares) or NCI H460-Akt1 cells (open triangles) were seeded
in 96-well plates in medium containing 0.5% serum. After 24h cells were
treated with different concentrations of doxorubicin, cisplatin, or
Mitoxantrone as indicated and incubated for another 72h at 371C. Cell
viability was then determined with a standard XTT assay as described in
‘Materials and methods’. Values are the mean of at least three independent
experiments.
Table 1 Chemosensitivit y of control transfected NCI H460 cells or NCI
H460-Akt1 cells
NCI H460
Compound IC50 (mM) (Control) IC50 (mM) (Akt1) Resistance factor
5-FU 0.03 0.09 3
Cisplatin 0.6 5.6 9.3
Doxorubicin 0.055 0.78 14
Paclitaxel 0.002 0.005 2.5
Mitoxantrone 0.005 0.1 20
Values were determined as average from at least three independent experiments
performed as quadruplicates. The resistance factor was calculated as the IC50 value of
NCI H460-Akt1 cells divided by the IC50 value of control transfected NCI H460 cells.
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tosis is already initiated in control cells but not yet visible by DNA
fragmentation in CA-Akt1-transfected cells. The optimal time
points and concentrations were found to be 20mM cisplatin
(incubation time 36h) and doses between 150 and 400nM
Mitoxantrone (incubation time 24h) (data not shown). Further
experiments were conducted using these compounds at the
indicated concentrations.
The activation of certain caspases is indicative of specific
pathways that are activated in order to execute apoptotic stimuli
(e.g. death receptor-mediated activation of caspases 8 and 10 or
activation of caspase 9 by the apoptosome (Peter and Krammer,
1998; Zou et al, 1999). Upon induction of caspase cascades, a
subset of cellular caspase downstream target proteins are
proteolytically cleaved. Poly-ADP-ribose polymerase (PARP), one
such target protein, is one of the earliest proteins targeted for a
specific cleavage to a 89-kDa C-terminal fragment with a reduced
catalytic activity and a 24kDa N-terminal peptide, which retains
the DNA-binding domains during the initiation of apoptosis (Peter
and Krammer, 1998).
For the initial examination of caspase activation in Akt-
mediated chemoresistance, we treated NCI H460-Akt1 cells and
control cells with 20mM cisplatin for 36h. Subsequently, immuno-
blots with antibodies specific for proteolytic cleavage of initiator
and effector caspases as well as the DNA repair enzyme PARP were
performed.
Control cells treated with cisplatin showed activation of initiator
caspases 8 and 9, effector caspases 3 and 7 as well as the caspase
target PARP (Figure 3A and B, left panels). In contrast, cleavage of
caspases 8, 9, and 7 in NCI H460-Akt1 cells was greatly diminished,
while no cleavage of caspase 3 and PARP was observed at these
time points (Figure 3A and B, right panels). Overall, caspase
activation upon treatment with Mitoxantrone (150nM for 24h) was
much weaker as compared to treatment with cisplatin (data not
shown).
Colorimetric caspase activity assays were conducted in order to
further substantiate the observation of differential caspase
activation in CA-Akt1 transfected NCI H460 cells. After incubation
with either Mitoxantrone (400nM; 24h incubation time) or
cisplatin (20mM; 36h incubation time), lysates from control cells
exhibited a significantly stronger caspase 3 and 9 activity
compared to cells expressing constitutively activated Akt1
(Figure 3C). Caspase 8 activity was induced to 5.3pmolmin
 1 in
control cells after cisplatin treatment compared to 1.4pmolmin
 1
in untreated cells. No increase in caspase 8 activity was detected
for NCI H460-Akt1 cells incubated with cisplatin. Treatment with
Mitoxantrone led to a slight but statistically not significant
induction of caspase 8 activity in both control and NCI H460-
Akt1 cells. Taken together, activation of both, initiator and effector
caspases, is quantitatively reduced and kinetically delayed in NCI
H460-Akt1 cells. However, no general qualitative differences were
observed, indicating that ectopic expression of CA-Akt1 is only
capable of delaying certain apoptotic pathways, but not of
completely suppressing the activity of specified caspases.
It has been described that activated Akt1 can influence the onset
of apoptosis by interfering with proteins from the mitochondrial
pathway of apoptosis (Datta et al, 1997; Pugazhenthi et al, 2000).
Furthermore, the induction of apoptosis by chemotherapy in NCI
H460 cells has been shown to be dependent on a functional
mitochondrial pathway (Ferreira et al, 2000). The initial step is the
release of cytochrome c from the mitochondria by proteins of the
Bcl-2 family. To exploit the potential chemoprotective role of Bcl-2
family proteins in NCI H460-Akt1 cells, the expression of Bcl-2,
Bfl-1, Bcl-xL, Bax, and Bcl-xs was investigated after exposure to
Mitoxantrone or cisplatin as described above (Figure 4). The
expression of Bcl-2 and Bfl-1 proteins was unchanged in NCI
H460-Akt1 cells vs control cells, regardless of chemotherapeutic
treatment, while Bax expression was induced by Mitoxantrone and
cisplatin to a similar extent in both cell transfectants. The
expression of Bcl-xs was barely detectable (data not shown). Most
notably, Bcl-xL protein levels were increased in NCI H460-Akt1
cells compared to control cells, which might account for an Akt1-
mediated antiapoptotic mechanism.
For further analysis of the mitochondrial apoptotic pathway, we
determined the release of cytochrome c from mitochondria.
Therefore, lysates from control and NCI H460-Akt1 cells treated
with 400nM Mitoxantrone or 20mM cisplatin for 8h, respectively,
were fractionally centrifuged. Cytosolic and mitochondrial con-
centrations of cytochrome c were determined by ELISA as
described in ‘Materials and methods’. As shown in Figure 5,
incubation with chemotherapeutics induced cytochrome c release
from mitochondria into the cytosol, thereby increasing the
cytosolic concentration of cytochrome c from approximately 30
to 75%. No differences were observed between control and NCI
H460-Akt1 cells, indicating that activated Akt1 did not prevent the
release of cytochrome c from the mitochondria. Caspase 9 may be
phosphorylated and thereby inactivated by Akt upon phosphor-
ylation at serine 198 (Cardone et al, 1998). However, we only
observed very subtle differences in the caspase 9 phosphorylation
(data not shown), making selective caspase 9 inactivation unlikely
to be causative for Akt1-mediated chemoresistance.
Figure 3 (A) Activation of initiator caspases after treatment of NCI
H460 cells with cisplatin. Control transfected NCI H460 cells or NCI
H460-Akt1 cells were grown in medium containing 0.5% serum overnight
and afterwards treated with cisplatin (20mM) for 36h. Cell lysates were
analysed by immunoblotting with antibodies specific for caspase 8 or
caspase 9 as indicated. (B) Activation of effector caspases and PARP after
treatment of NCI H460 cells with cisplatin. Lysates from cells treated as
described above were prepared and analysed by immunoblotting with
antibodies specific for caspase 3, caspase 7, and PARP as indicated. (C)
Enzymatic assays of caspase activity. Cells were treated as described above.
Additionally, samples from cells treated with 400nM Mitoxantrone for 24h
were included. Caspase 3, 8, and 9 activities from lysates were determined
by a colorimetric assay as described in ‘Materials and methods’.
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response of tumour cells towards chemotherapeutic agents
includes the activation of the p53 pathway. Activation of p53
occurs via multiple serine phosphorylations by serine/threonine
kinases such as ATM, ATR, Chk2 or DNA-PK, leading to
stabilisation, activation, and translocation into the nucleus, where
p53 acts as transcription factor interfering with transcription of
multiple genes involved in cell cycle regulation, DNA repair, and
apoptosis (Sionov and Haupt, 1999). To investigate whether
constitutive activation of Akt1 interferes with the activation of
p53, control cells and NCI H460-Akt1 cells were treated with 20mM
cisplatin for 2, 4, 8, 16, and 36h, respectively. Lysates were
analysed with specific antibodies for expression levels of p53 and
the p53 antagonist MDM2. The results are summarised in Figure 6:
NCI H460-Akt1 cells showed a similar kinetics of p53 upregulation
as compared to control cells. A delayed onset of upregulation,
however, was observed for MDM2, which was induced as early as
4h of cisplatin exposure in control transfected cells and remained
stable for at least 36h. MDM2 upregulation was observed only at
8h of cisplatin exposure in NCI H460-Akt1 cells and declined
already after 16h. Very similar results of delayed MDM2
upregulation in NCI H460-Akt1 vs control cells were observed
when cells were treated with 400nM Mitoxantrone for time points
between 2 and 24h (data not shown).
From our data, we conclude that the expression of constitutively
activated Akt1 in NCI H460 human NSCLC cells can cause partial
resistance towards a class of chemotherapeutics, most pronounc-
edly towards drugs interacting with DNA. Molecular pathway
analyses revealed that CA-Akt increases the apoptotic threshold or
time course of onset of multiple apoptotic pathways. However, the
sole ectopic expression of a constitutively active form of Akt1 does
not suffice to completely suppress the chemotherapy-induced
activation of defined apoptotic triggers.
DISCUSSION
PKB/Akt has been described as a central mediator of antiapoptotic
signalling and as a mediator of reduced sensitivity of cancer cells
towards chemotherapeutic agents (West et al, 2002). Recently, we
could show that expression of constitutively active farnesylated
Akt1 (CA-Akt) renders MCF10A mammary epithelial cells and
A549 non-small-cell lung cancer (NSCLC) cells more resistant to
the treatment with cell cycle independent chemotherapeutics such
as cisplatin and Mitoxantrone (Schmidt et al, 2002). In this study,
we examined the effects of CA-Akt expression in human NCI H460
NSCLC cells regarding chemosensitivity and the modulation of
apoptotic pathways. Utilising an expression vector encoding Akt1
devoid of its PH domain and a C-terminally fusion of a
farnesylation sequence described recently (Schmidt et al, 2002),
we generated stable NCI H460 cell clones expressing CA-Akt. This
consititutive activation of PKB/Akt resulted in a decreased
sensitivity of NCI H460 cells towards a panel of chemotherapeutic
agents currently used in the clinic (Table 1). It has to be noted that
we observed the mediation of chemoresistance by CA-Akt
primarily under conditions of low serum and to a far lesser extent
in full growth medium. We explain this observation by the fact that
endogenous Akt can be activated by serum components (Figure 1).
Figure 4 Expression analysis of Bcl-2 family proteins in NCI H460 cells.
Control transfected NCI H460 cells or NCI H460-Akt1 cells were grown in
medium containing 0.5% serum overnight (-) and afterwards treated with
150nM Mitoxantrone (Mito) for 24h or 20mM cisplatin (CP) for 36h,
respectively. Equal amounts of cell lysates were analysed by immunoblot-
ting with antibodies specific for Bcl-2, A1/Bfl-1, Bax, and Bcl-xL as indicated.
Figure 5 Cytochrome c release from mitochondria after treatment of
NCI H460 cells with Mitoxantrone or cisplatin. Control transfected NCI
H460 cells or NCI H460-Akt1 cells were grown in medium containing 0.5%
serum overnight (-) and treated with 400nM Mitoxantrone (Mito) or 20mM
cisplatin (CP) for 8h, respectively. (A) Cell lysates were fractionally
centrifugated and analysed with a cytochrome c ELISA as described in
‘Materials and methods’. Each value was determined as triplicate. (B)
Aliquots of cell lysates were analysed by Western blotting with an antibody
specific for caspase 8 as a control for cellular fractionation.
Figure 6 Induction of p53 in Akt1-transfected NCI H460 cells. Control
transfected NCI H460 cells or NCI H460-Akt1 cells as indicated were
grown in medium containing 0.5% serum and treated with cisplatin (20mM)
for 2, 4, 8, 16, and 36h, respectively. At each time point, cell lysates were
generated and analysed by immunoblotting with antibodies specific for p53,
MDM2, and b-actin.
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Akt may not provide a further survival advantage compared to
active endogenous Akt alone. The most profound desensitisation
was detected for Mitoxantrone, doxorubicin, and cisplatin
(Figure 2). These agents can exert their cytotoxic mode of action
by inducing DNA damage irrespective of the cell cycle phase.
Mitoxantrone and doxorubicin have been described to intercalate
with DNA at high concentrations, but also to inhibit Topoisome-
rase II, thereby leading to persistant double-strand breaks of DNA
(Bodley et al, 1989; Boland et al, 2000). Cisplatin has been shown
to alkylate DNA and to lead to the activation of caspase 8 with
subsequent initiation of a caspase cascade (Ferreira et al, 2000).
Surprisingly, no significant modulation of chemosensitivity was
observed towards cell cycle specific drugs such as paclitaxel. Thus,
we can exclude that the chemoresistance in NCI H460-Akt1 cells is
simply due to the reduced growth rate of the transfectants.
To further study the molecular mechanisms underlying the CA-
Akt-mediated altered chemosensitivity, we analysed various
apoptotic pathways. In summary, quantitative or kinetic differ-
ences were observed in the suppression or delay of molecular
pathways of apoptosis induction, but no complete inhibition could
be accounted to CA-Akt1. Different pathways for the induction of
apoptosis have been discovered, for example, the activation of
death receptors or the release of cytochrome c from the
mitochondria. Both pathways comprise the activation of caspase
cascades, leading to cell death. The proteolytic cascade consists of
initiator caspases such as caspases 8, 9, and 10, and downstream
effector caspases, for example, caspase 3 and 7 (Nunez et al, 1998).
Akt1 has been described to suppress apoptotic stimuli by
interfering with apoptotic pathways, for example, by phosphoryla-
tion of caspase 9 (Cardone et al, 1998) or the proapoptotic Bcl-2
homologue Bad (Datta et al, 1997). Analysing the activation of
caspases upon stimulation with Mitoxantrone or cisplatin at
concentrations and time points leading to DNA fragmentation in
control cells but not in NCI H460-Akt1 cells exhibited a kinetic
delay as well as quantitative, but not qualitative differences in the
activation of the caspase cascade. Western Blot analysis revealed
that upon treatment with cisplatin control cells showed cleavage of
both initiator caspases 8 and 9 as well as the effector caspases 7
and 3 and the caspase 3/7 target protein PARP, while only caspase
8 was weakly activated in NCI H460-Akt1 cells at that time point
(Figure 3A and B). These findings were supported by caspase
activity assays showing a profound reduction in the activation of
initiator caspases 8 and 9 as well as the effector caspase 3 in NCI
H460-Akt1 cells compared to control cells upon treatment with
cisplatin, while upon treatment with Mitoxantrone an altered
activation was only observed in caspase 9 and 3 as caspase 8 is
hardly activated by Mitoxantrone at all (Figure 3C).
The mitochondrial apoptosis pathway plays an important role in
the execution of chemotherapy-induced apoptosis. Cytosolic
cytochrome c binds to Apaf-1 and together with caspase 9 forms
a complex termed ‘apoptosome’. Within the ‘apoptosome’, caspase
9 is proteolytically cleaved and activated (Cain et al, 2000). Yet,
neither differences in the release of cytochrome c from mitochon-
dria (Figure 5) nor the expression of the ‘apoptosome’ associated
protein Apaf-1 (data not shown) were detected between CA-Akt
and control cells upon treatment with cisplatin or Mitoxantrone.
Only very subtle differences in the caspase 9 phosphorylation,
which is known to be inactivated by Akt1 (Cardone et al, 1998),
could be observed in NCI H460-Akt1 cells (data not shown),
making selective caspase 9 inactivation unlikely to be causative for
Akt1-mediated chemoresistance. Other proteins involved in
mitochondrial membrane integrity are members of the Bcl-2
family. One potential mechanism by which Akt1 may interfere with
proapoptotic members of this family is the inhibition of a Bax
conformational change preventing disruption of mitochondrial
inner membrane potential and caspase 3 activation (Yamaguchi
and Wang, 2001). Analysis of the expression levels of Bcl-2 and Bfl-
1 or the induction of Bax expression after exposure to
Mitoxantrone or cisplatin did not reveal differences between NCI
H460-Akt1 and control cells. In contrast, protein levels of
antiapoptotic Bcl-xL were increased in NCI H460-Akt1 cells
compared to control cells. Bcl-xL overexpression has been shown
to protect cells from p53-mediated apoptosis (Schott et al, 1995).
Thus, the induction of Bcl-xL overexpression might account for an
Akt1-mediated antiapoptotic mechanism.
The p53 tumour-suppressor protein pathway also plays an
important role in the transduction of proapoptotic signals towards
various forms of cellular stress, such as DNA damage. Upon DNA
damage, p53 is activated via phosphorylation by Chk1, Chk2,
ATM, and ATR, and may translocate into the nucleus, where it
induces the transcription of pro-apoptotic proteins such as Bax, as
well as its antagonist MDM2 as a negative feedback loop (Sionov
and Haupt, 1999). PKB/Akt has been shown to phosphorylate
MDM2 at Ser 166 and Ser 186 (Mayo and Donner, 2001). After
phosphorylation, MDM2 may likewise translocate from the
cytoplasm into the nucleus, where it can block p53 transactivation
and promote p53 degradation. Our results show an induction of
p53 and successively MDM2 upon treatment with cisplatin
(Figure 6). However, induction of MDM2 expression as a p53-
regulated gene was delayed in CA-Akt-expressing cells compared
to control cells. This may suggest that the onset of p53
transactivation itself is delayed by the expression of CA-Akt.
Moreover, expression of MDM2 and p53 declined after 36h in NCI
H460-Akt1 cells, but no decline was detected in control cells.
In summary, our results show that ectopic expression of
constitutively activated Akt1 in NCI H460 human NSCLC cells
can cause partial resistance towards a class of chemotherapeutics
and may increase the apoptotic threshold or delay time course of
certain apoptotic pathways, but does not completely suppress the
activity of specified caspases or the chemotherapy-induced
apoptosis. It is interesting to note that chemoresistance is only
conferred towards non-cell cycle-dependent chemotherapeutics
primarily interfering with DNA. From this point of view, it will be
worthwhile to study potential target proteins of Akt directly
involved in the sensing of DNA damage such as Chk1 and 2,
ATM, ATR, and other proteins involved in the DNA damage
checkpoint pathway. Furthermore, our data support the notion
that a pharmaceutical drug-inhibiting Akt activity may not
be sufficient to kill cancer cells on its own, but may be used to
lower the apoptotic threshold and to resensitise chemoresistant
tumours in combination treatment with defined chemotherapeutic
drugs.
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